Cargando…

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice

Advances in the development of novel treatment options for hemophilia A are prevalent. However, the anti–factor VIII (FVIII) neutralizing antibody (inhibitor) response to existing FVIII products remains a major treatment challenge. Although some novel products are designed to function in the presenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lundgren, Taran S., Denning, Gabriela, Stowell, Sean R., Spencer, H. Trent, Doering, Christopher B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Gene Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043920/ https://www.ncbi.nlm.nih.gov/pubmed/35286375 http://dx.doi.org/10.1182/bloodadvances.2021006359

Ejemplares similares

CD14(+)/CD31(+) monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII
por: Elnaggar, Muhammad, et al.
Publicado: (2022)

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII
por: Russell, Athena L., et al.
Publicado: (2021)

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A
por: Johnston, Jennifer M., et al.
Publicado: (2012)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020)

Transcutaneous ultrasound-mediated gene delivery into canine livers achieves therapeutic levels of factor VIII expression
por: Manson, Megan A., et al.
Publicado: (2022)

Intrathymic AAV delivery results in therapeutic site-specific integration at TCR loci in mice
por: Calabria, Andrea, et al.
Publicado: (2023)

AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage
por: Binny, Christopher, et al.
Publicado: (2012)

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
por: von Drygalski, Annette, et al.
Publicado: (2022)

THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing
por: von Soosten, Laura, et al.
Publicado: (2022)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A
por: Stem, Christopher, et al.
Publicado: (2021)

Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice
por: Lange, Amy M, et al.
Publicado: (2016)

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1
por: Carlisle, Robert C., et al.
Publicado: (2009)

Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells
por: Zhang, Fang, et al.
Publicado: (2007)

CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells
por: Flynn, Rowan, et al.
Publicado: (2015)

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2021)

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
por: Ghione, Paola, et al.
Publicado: (2022)

In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4
por: Wang, Hongjie, et al.
Publicado: (2022)

In vivo HSC prime editing rescues sickle cell disease in a mouse model
por: Li, Chang, et al.
Publicado: (2023)

Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells
por: Vavassori, Valentina, et al.
Publicado: (2023)

Adenine base editor–mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation
por: Hardouin, Giulia, et al.
Publicado: (2023)

Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing
por: Sun, Zhengxu, et al.
Publicado: (2023)

A comprehensive landscape of transcription profiles and data resources for human leukemia
por: Luo, Mei, et al.
Publicado: (2023)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway
por: Patel, Seema R., et al.
Publicado: (2022)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A
por: Knöbl, Paul
Publicado: (2018)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

CT-157 Another Rare Case of COVID-19 Vaccine Induced Acquired Hemophilia
por: Ismail, Asmaa M.
Publicado: (2022)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
por: Chen, Zhen-Ping, et al.
Publicado: (2018)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
por: Long, Brian R., et al.
Publicado: (2021)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Adeno-associated Virus (AAV) Capsid Chimeras with Enhanced Infectivity Reveal a Core Element in the AAV Genome Critical for both Cell Transduction and Capsid Assembly
por: Viney, Lydia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qdtqda1j7kb3s932heogj40sjk